Literature DB >> 17414998

Leukodystrophies: clinical and genetic aspects.

Gilles Lyon1, Aviva Fattal-Valevski, Edwin H Kolodny.   

Abstract

The leukodystrophies comprise an ever-expanding group of rare central nervous system disorders with defined clinical, pathological, and genetic characteristics. The broader term, leukoencephalopathy, is applied to all brain white matter diseases, whether their molecular cause is known. Magnetic resonance imaging has helped to elucidate new forms of leukodystrophy as well as to permit longitudinal studies of disease progression. The white matter abnormality may appear similar in different forms of leukodystrophy so that in most cases, further studies such as magnetic resonance spectroscopy, tissue biopsies, enzyme studies, and molecular DNA analyses are needed to pinpoint the specific diagnosis. The primary inherited leukoencephalopathies include dysmyelinating, hypomyelinative, and vacuolating forms. Metabolic and vascular causes account for most of the secondary forms, but other inherited syndromes are recognized that have their onset in childhood or adult life and are characterized by distinctive clinical and neuropathologic features. This review discusses some of the mechanisms that have been proposed to explain deficiencies of myelin and the molecular genetic bases underlying these disorders.

Entities:  

Mesh:

Year:  2006        PMID: 17414998     DOI: 10.1097/RMR.0b013e31804c99d4

Source DB:  PubMed          Journal:  Top Magn Reson Imaging        ISSN: 0899-3459


  14 in total

1.  Sporadic diffuse leucoencephalopathy with axonal spheroids: report of a profuse and rapid cortical-spinal degeneration.

Authors:  A Maues De Paula; B Michel; D W Dickson; Z K Wszolek; J F Pellissier
Journal:  Neurol Sci       Date:  2011-10-18       Impact factor: 3.307

2.  A whole-genome scan in a large family with leukodystrophy and oligodontia reveals linkage to 10q22.

Authors:  Eliane Chouery; Valérie Delague; Nadine Jalkh; Nabiha Salem; Jessy Kfoury; Diana Rodriguez; Brigitte Chabrol; Odile Boespflug-Tanguy; Nicolas Lévy; Jean Louis Serre; André Mégarbané
Journal:  Neurogenetics       Date:  2010-08-19       Impact factor: 2.660

3.  Insights into the dynamics of hereditary diffuse leukoencephalopathy with axonal spheroids.

Authors:  J A Van Gerpen; C Wider; D F Broderick; D W Dickson; L A Brown; Z K Wszolek
Journal:  Neurology       Date:  2008-09-16       Impact factor: 9.910

Review 4.  Systematic approaches to central nervous system myelin.

Authors:  Patricia de Monasterio-Schrader; Olaf Jahn; Stefan Tenzer; Sven P Wichert; Julia Patzig; Hauke B Werner
Journal:  Cell Mol Life Sci       Date:  2012-03-23       Impact factor: 9.261

Review 5.  Adult-onset leukoencephalopathy with neuroaxonal spheroids and pigmented glia: report of five cases and a new mutation.

Authors:  Kirk Kleinfeld; Bret Mobley; Peter Hedera; Adam Wegner; Subramaniam Sriram; Siddharama Pawate
Journal:  J Neurol       Date:  2012-09-30       Impact factor: 4.849

6.  Diffusion tensor MRI as a biomarker in axonal and myelin damage.

Authors:  Wint Yan Aung; Soe Mar; Tammie Ls Benzinger
Journal:  Imaging Med       Date:  2013-10-01

7.  HEREDITARY MYELOPATHIES.

Authors:  John K Fink
Journal:  Continuum (N Y)       Date:  2008-06-01

8.  Multiple sclerosis-like neurological manifestations in a coeliac patient: nothing is as it seems.

Authors:  Pasquale Mansueto; Laura Di Stefano; Alberto D'Alcamo; Antonio Carroccio
Journal:  BMJ Case Rep       Date:  2012-07-04

Review 9.  Inborn errors of metabolism and motor disturbances in children.

Authors:  A García-Cazorla; N I Wolf; M Serrano; B Pérez-Dueñas; M Pineda; J Campistol; E Fernández-Alvarez; J Colomer; S DiMauro; G F Hoffmann
Journal:  J Inherit Metab Dis       Date:  2009-10       Impact factor: 4.982

Review 10.  Neurocognitive impairments and brain abnormalities resulting from opioid-related overdoses: A systematic review.

Authors:  Erin L Winstanley; James J Mahoney; Felipe Castillo; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2021-06-24       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.